Skip to main content

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERSThe shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Tuesday, May 19, 2020, at 5 p.m. in the Company’s offices, Scheelevägen 22 in Lund, Sweden.INFORMATION RELATING TO THE CORONA VIRUS
As a result of the Corona virus, Active Biotech kindly asks the shareholders not to participate in this years’ Annual General Meeting in person. Instead, Active Biotech encourages shareholders to carefully consider the possibility of participating in the meeting by way of proxy or advance voting (see below). Any questions to be raised by shareholders at the Meeting can be sent to the Company by e-mail to susanne.jonsson@activebiotech.com in advance of the Meeting. Written answers to the questions raised will be posted on the Company’s website after the Meeting.
ENTITLEMENT TO PARTICIPATE
Shareholders who wish to participate in the Meeting must (i) be recorded in the register of shareholders maintained by Euroclear Sweden AB on Wednesday, May 13, 2020, and (ii) notify the Company of their intention to participate in the Meeting not later than on Wednesday, May 13, 2020.
     Shareholders who have trustee-registered their shares must register the shares in their own name to be entitled to participate in the Meeting. Such registration, which may be temporary, must be completed on Wednesday, May 13, 2020. Accordingly, shareholders must inform the trustee of this request in ample time prior to this date.
There are 145,236,480 shares and votes in Active Biotech. The Company holds no treasury shares.
NOTICE OF PARTICIPATION
Notice of participation in the Meeting can be made in writing to Active Biotech AB (publ), Attn: Susanne Jönsson, P.O. Box 724, SE-220 07 Lund, Sweden, by telephone +46 (0)46-19 20 00 or by e-mail to susanne.jonsson@activebiotech.com. The notice shall include name, personal/corporate identity number, number of shares held, daytime telephone number and, if applicable, the number of advisors (not more than two) that will accompany the shareholder at the Meeting.
Shareholders represented by proxy shall issue a dated and signed power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a certified copy of a registration certificate or corresponding document indicating the authorized signatories of the legal entity shall be appended. The original power of attorney and, where applicable, the certificate should be submitted to the Company at the address indicated above well in advance of the Meeting. Proxy forms are provided at the Company’s website, www.activebiotech.com, and sent to shareholders that so request.
ADVANCE VOTING
The shareholders may exercise their voting rights at the Annual General Meeting by voting in advance. Active Biotech encourages all shareholders to use this opportunity in order to minimise the number of participants attending the Meeting in person and thus reduce the spread of the Corona virus.
A special form shall be used for advance voting. The form is available on Active Biotech’s website, www.activebiotech.com. A shareholder exercising its voting right through advance voting do not need to notify the Company of its attendance to the Meeting. The advance voting form is considered as the notification of attendance to the Meeting.The completed voting form must be submitted to Active Biotech so it is received no later than Wednesday, May 13, 2020. The completed and signed form shall be sent to the postal address or e-mail address stated under the section “Notice of participation” above. If the shareholder is a legal entity or is voting in advance by proxy, a certificate of incorporation or a corresponding document shall be enclosed to the form. The shareholder may not qualify the advance vote with special instructions or conditions. If so, the vote is invalid. Further instructions and conditions is included in the form for advance voting.
PROPOSED AGENDA
Opening of the MeetingElection of Chairman of the MeetingPreparation and approval of the voting listElection of one or two persons to verify the minutesApproval of the agenda for the MeetingDetermination of whether the Meeting has been duly convenedPresentation of the Annual Report and the Auditors’ Report, and the Consolidated Accounts and the Auditors’ Report for the GroupResolution concerning the adoption of the Income Statement and the Balance Sheet, and the Consolidated Income Statement and the Consolidated Balance SheetResolution concerning the disposition of the Company’s results pursuant to the adopted Balance SheetResolution on discharge from liability of the members of the Board of Directors and the CEODetermination of the number of members and alternate members of the Board of Directors and the number of auditors and alternate auditorsDetermination of fees payable to the Board of Directors and auditorElection of the Board of Directors, Chairman of the Board and auditor        a) re-election of Michael Shalmi,
        b) re-election of Uli Hacksell,
        c) re-election of Peter Thelin,
        d) new election of Axel Glasmacher,
        e) new election of Aleksandar Danilovski,
        f) new election of Elaine Sullivan,
        g) re-election of Michael Shalmi as Chairman of the Board, and
        h) re-election of KPMG AB as auditor of the Company.
Resolution concerning Election CommitteeThe Board of Director’s proposal regarding guidelines for remuneration of senior executivesThe Board of Director’s proposal regarding amendment of the Articles of AssociationThe Board of Director’s proposal regarding implementation of a long-term performance-based incentive program for the Company’s employeesMGA Holding AB’s proposal regarding implementation of a long-term performance-based incentive program for Board membersThe Board of Director’s proposal regarding share issue authorizationClosing of the MeetingFor full notice of Active Biotech’s Annual General Meeting on May 19, including proposed resolutions, see attached PDF or www.activebiotech.com.DOCUMENTATION, ETC.
The Annual Report and other supporting resolution documentation will be held available at the Company’s premises at Scheelevägen 22 in Lund, Sweden, and on the Company’s website, www.activebiotech.com, not later than three weeks prior to the Meeting. The documents will be sent to shareholders who request a copy and specify their postal address. Shareholders are reminded of their right to request information under Chapter 7, Section 32 of the Swedish Companies Act.
For information about the processing of your personal data, please refer to https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Active Biotech’s corporate registration number is 556223-9227 and its registered office is in Lund, Sweden.Lund, April 2020
The Board of Directors of Active Biotech AB (publ)
AttachmentNotice of AGM_2020_(en)

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.